- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT01735539
Dysfunction of Nutritive Blood Flow as a Determinant of Anabolic Resistance With Age; the Role of Amino Acids in Modulating Muscle Metabolism (Ajinomoto1A)
Dysfunction of Nutritive Blood Flow as a Determinant of Anabolic Resistance in Older People; The Role of Essential Amino Acids in Modulating Muscle Protein Metabolism; Bolus vs. Pulse Feeding Strategies and the Ability of Arginine to Rejuvenate Microvascular Responsiveness.
The investigators plan to measure changes in muscle protein metabolism in response to feeding, comparing between a single large essential amino acid (EAA) feed (the normal building blocks of protein) and the provision of the same dose in 4 smaller feeds at 45min intervals. The investigators will perform this study in healthy older (65-75y) and younger (18-28) men. The investigators will also explore how feeding affects muscle blood flow as this is important in the delivery of the nutrients we eat to the muscle where they are used.
The investigators plan to supplement the feed with arginine, a safe and widely found non-essential amino acid, to explore if this can improve muscle blood flow.
Study Overview
Status
Conditions
Detailed Description
We will provide a 15g mixed essential amino acid feed or 4 x 3.75g.
There is sexual dimorphism thus initially we will just recruit males. Powering calculations dictate n=8 in each group.
We will use well established stable isotope tracer techniques (with 13C6 Phenylalanine) to measure muscle protein synthesis and breakdown by Gas Chromatography - combustion - isotope ratio mass spectroscopy.
We will measure leg blood flow by phase shift Doppler and muscle microvascular flow by contrast enhanced ultrasound.
Study Type
Enrollment (Anticipated)
Phase
- Not Applicable
Contacts and Locations
Study Locations
-
-
-
Derby, United Kingdom, DE23 6PF
- University of Nottingham School of Graduate Entry Medicine and Health
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- age 65-75 or 18-28
Exclusion Criteria:
- BMI >30
- Diabetes
- Beta blocker or steroid use
- Established cerebrovascular, peripheral vascular or ischaemic heart disease.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Non-Randomized
- Interventional Model: Parallel Assignment
- Masking: Double
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
|---|---|
|
Experimental: Old Bolus
15g EAA bolus
|
Oral; in aqueous solution
Other Names:
|
|
Experimental: Old Arginine
15g EAA Bolus supplemented with 3g Arginine
|
Oral; in aqueous solution
|
|
Experimental: Young Bolus
15g EAA bolus
|
Oral; in aqueous solution
Other Names:
|
|
Experimental: Young Pulse
4 x 3.75g Mixed EAA Pulses
|
Oral; in aqueous solution
|
|
Experimental: Old Pulse
4 x 3.75g Mixed EAA Pulses
|
Oral; in aqueous solution
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Muscle Protein Synthesis (FSR, fractional synthetic rate, %/hr)
Time Frame: Across 6hr study
|
We measure FSR when fasted and again 0-90, 90-180 and 180-240 post feed.
|
Across 6hr study
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Muscle Protein Breakdown (MPB)
Time Frame: Across 6hr study
|
MBP is measured during fasting and 0-90, 90-180 and 180-240mins post feed.
|
Across 6hr study
|
|
Whole leg blood flow
Time Frame: Across a 6hr study
|
We measure common femoral blood flow by doppler ultrasound when fasted and again 0-90, 90-180 and 180-240 post feed.
|
Across a 6hr study
|
|
Muscle Microvascular Blood flow
Time Frame: Across a 6hr study
|
We measure muscle microvascular flow using contrast enhanced ultrasound when fasted and again 0-90, 90-180 and 180-240 post feed.
|
Across a 6hr study
|
Collaborators and Investigators
Sponsor
Investigators
- Principal Investigator: Philip J Atherton, PhD, University of Nottingham
Publications and helpful links
Study record dates
Study Major Dates
Study Start
Primary Completion (Actual)
Study Completion (Anticipated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Estimate)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Other Study ID Numbers
- UNottingham F/3/2009
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
product manufactured in and exported from the U.S.
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Old Age (Focus; Not a Recognized Condition)
-
Universidad de ZaragozaIngesan-OHLACompletedPeople 60 Years of Age or Over 55 Years of Age With a Diagnosed Pathology and Preferably With a Recognized Physical and/or Cognitive DependencySpain
-
Dow University of Health SciencesActive, not recruitingPain Reduction | We Are Not Studying a Disease or ConditionPakistan
-
Trustees of Dartmouth CollegeRecruitingWe Are Not Studying a Disease or ConditionUnited States
-
VU University of AmsterdamCompletedWe Are Not Studying a Disease or Condition | The Study is Focused on People With Limited Health LiteracyNetherlands
-
Hennepin Healthcare Research InstituteCompletedAll Eligible ED Patients (Not Limited to a Particular Condition)United States
-
Federal University of São PauloFundação de Amparo à Pesquisa do Estado de São PauloCompletedOther Condition That May be a Focus of Clinical AttentionBrazil
-
University Hospital, RouenNot yet recruitingSleep Disorders Not Due to A Substance or Known Physiological ConditionFrance
-
Philips RespironicsCompletedSleep | Sleep Disorders Not Due to A Substance or Known Physiological ConditionUnited States
-
Rutgers, The State University of New JerseyRecruitingPhysical Disability | Muscle Atrophy or Weakness | Muscle Loss | Physical Inactivity | Delirium in Old Age | Hospital Acquired Condition | Weakness, MuscleUnited States
-
Max-Planck-Institute of PsychiatryCompletedSchizophrenia | Schizoaffective Disorder | Delusional Disorder | Schizotypal Disorder | Brief Psychotic Disorder | Shared Psychotic Disorder | Other Psychotic Disorder Not Due to A Substance or Known Physiological Condition | Unspecified Psychosis Not Due to a Substance or Known Physiological Condition and other conditionsGermany
Clinical Trials on 15g EAA bolus
-
United States Army Research Institute of Environmental...University of Arkansas; Eastern Michigan UniversityCompletedMuscle Protein Synthesis | Whole-body Protein BalanceUnited States
-
United States Army Research Institute of Environmental...University of Arkansas; Eastern Michigan UniversityCompletedEnergy DeficitUnited States
-
Texas A&M UniversityUniversity of ArkansasCompletedNon-small Cell Lung CancerUnited States
-
Wyeth is now a wholly owned subsidiary of PfizerTerminatedDiabetes Mellitus | Diabetic Neuropathy, Painful
-
Dirk FischerCompleted
-
University of NottinghamAjinomoto Co., Inc.Unknown
-
The Swedish School of Sport and Health SciencesRecruitingObesity | Sarcopenia | Aging | Sarcopenic ObesitySweden
-
United States Army Research Institute of Environmental...University of Arkansas; Norwegian Defense Research EstablishmentCompletedWeight Loss | Military Operational Stress Reaction | Malnutrition (Calorie) | Muscle WastingNorway
-
University of ArkansasWithdrawn
-
Istituto Auxologico ItalianoRecruitingWeight Loss | Obesity MorbidItaly